Form 6-K NovaBridge Biosciences For: Jun 16
Tweet
Share
E-mail
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2026
Commission File Number: 001-39173
NovaBridge Biosciences
2440 Research Boulevard, Suite 400
Rockville, MD 20850
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On June 16, 2026, NovaBridge Biosciences issued a press release, a copy of which is furnished herewith as Exhibit 99.1.
EXHIBIT INDEX
Exhibit No. |
Description |
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
NovaBridge Biosciences |
||
|
|
||
|
By |
: |
/s/ Xi-Yong Fu |
|
Name |
: |
Xi-Yong (Sean) Fu |
|
Title |
: |
Chief Executive Officer |
Date: June 16, 2026
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Modular Medical Announces Commercial Availability of Pivot Tubeless Insulin Patch Pump Ahead of Commercial Expansion
- Rail Vision Announces Recent Major Achievements with Industry Leaders in the US and Local Markets
- Federated Hermes launches active, short-duration fixed-income ETF
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
